Open Veils · Answer
Best treatment for LADA
LADA sits at the autoimmune-metabolic crossroads where conventional Type 2 protocols actively accelerate beta-cell destruction. The suppressed clinical priority is beta-cell preservation from diagnosis — not reactive insulin rescue after the cells are gone. Sulfonylureas, still widely prescribed, are particularly condemned by researchers like Jerry Palmer and Åke Lernmark as accelerating autoimmune beta-cell loss. The window for meaningful intervention is early and narrow.
Evidence
- Gary Taubes and Nina Teicholz's low-carbohydrate metabolic framework offers the first line of defence: radically reducing glucose demand on stressed beta cells slows the autoimmune attrition curve before pharmaceutical intervention is even considered.
- The most underreported clinical argument — made explicitly in a December 2025 Cleveland Clinic editorial — is that LADA should be treated as Type 1 from diagnosis, with insulin initiated immediately.
- Researcher Åke Lernmark's work on GAD65 autoantibodies — the primary LADA diagnostic marker — underscores that antibody titre correlates with progression speed.
- The emerging frontier, flagged in a September 2026 Endocrinology Research and Practice review, is immunotherapy — specifically low-dose anti-CD3 monoclonals and GAD-alum vaccine trials (the DiAPREV-IT and DIAGNODE studies) aimed at halting autoimmune destruction before the beta-cell mass crosses the clinical threshold.
- Weston A. Price Foundation researchers and Jack Kruse additionally point to fat-soluble vitamin sufficiency — particularly vitamins D and K2 — and circadian-aligned eating as modulators of the autoimmune inflammatory load driving LADA progression, though this remains outside any trial framework.
